RecruitingPhase 2NCT06838676
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
Studying Diffuse intrinsic pontine glioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Nationwide Children's Hospital
- Principal Investigator
- David S. Ziegler, MD, FRACPSydney Children's Hospitals Network
- Intervention
- ACT001(drug)
- Enrollment
- 60 enrolled
- Eligibility
- 39 years · All sexes
- Timeline
- 2025 – 2035
Study locations (20)
- Children's Hospital Colorado, Aurora, Colorado, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- Nicklaus Children's Hospital, Miami, Florida, United States
- Emory University/Children's Healthcare of Atlanta, Atlanta, Georgia, United States
- C.S. Mott Children's Hospital, Ann Arbor, Michigan, United States
- St. Louis Children's Hospital, St Louis, Missouri, United States
- Duke University Medical Center, Durham, North Carolina, United States
- Cincinnati Children's Hospital, Cincinnati, Ohio, United States
- Nationwide Children's Hospital, Columbus, Ohio, United States
- Children's Hospital of Philidelphia, Philidelphia, Pennsylvania, United States
- Texas Children's Hospital, Houston, Texas, United States
- Seattle Children's Hospital, Seattle, Washington, United States
- Sydney Children's Hospital, Randwick, New South Wales, Australia
- Queensland Children's Hospital, South Brisbane, Queensland, Australia
- Royal Children's Hospital, Melbourne, Victoria, Australia
- +5 more locations on ClinicalTrials.gov
Collaborators
Accendatech USA Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06838676 on ClinicalTrials.govOther trials for Diffuse intrinsic pontine glioma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07076498Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care RadiationM.D. Anderson Cancer Center
- RECRUITINGPHASE1, PHASE2NCT07501156H3K27M-specific Immune Effector Cells Targeting DMG/DIPGShenzhen Geno-Immune Medical Institute
- RECRUITINGPHASE1NCT06305910CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young AdultsOX2 Therapeutics
- RECRUITINGPHASE1NCT06221553Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPGChulalongkorn University
- RECRUITINGPHASE1NCT05544526CAR T Cells to Target GD2 for DMGUniversity College, London
- RECRUITINGPHASE1NCT05762419FUS Etoposide for DMGColumbia University
- ACTIVE NOT RECRUITINGPHASE1NCT05768880Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System TumorsSeattle Children's Hospital
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05615623Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPGInSightec